Super Session 6

The New Cross-Industry Playground

21 April 2021

14:00 - 15:30
The New Cross-Industry Playground

Super Session 6

14:00 - 15:30

In the world of exponential data and digital disruption, there are more stakeholders involved in R&D than ever before. Traditional business models across the drug discovery and development value chain are transitioning at an increasingly rapid pace. Likewise, the diversification of product pipelines has expanded beyond drugs to increasingly include medical devices, big data, and digital tools, through which we can better engage patients and harness the best of medicine. In this session, we take a look at this new field: who is involved, how are they working together, and what does this mean for the future of clinical trials from Academic, Pharmaceutical, Technology, and Regulatory perspectives? Likewise, what are the updates around the new Medical Device Regulations (MDR) – and how should SMEs prepare to take their first big steps towards getting their device(s) on the market?

Sponsored by:

AstraZeneca

AstraZeneca

Moderator(s): Dr. Jessica Shull - European Lead, Digital Therapeutics Alliance Ms. Sofia Nordgren - Director of Regulatory Affairs, Devicia

Speaker(s):

Dr. Jessica Shull - European Lead, Digital Therapeutics Alliance
Ms. Sofia Nordgren - Director of Regulatory Affairs, Devicia
Dr. Magnus Björsne - CEO, Astrazeneca BioVentureHub
Mr. Martin Olovsson - CEO and Co-Founder, Ondosis
Mr. Urban Roth - Client Center Leader Nordic, IBM
Dr. Sam Oddsson - Chief Medical Officer & Co-Founder, SidekickHealth

full program